Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Midterm Efficacy of SubcutAneous Implantable CardioVErter-Defibrillator in ≤ 18 Year-Old CHILDREN (SAVE CHILDREN-II Registry).

Journal of arrhythmia·2026
Same author

MitoSafe hypothesis: safeguarding mitochondrial morphology and innate immunity.

Trends in cell biology·2026
Same author

Epidemiology and outcomes in patients with out-of-hospital cardiac arrest without coma after return of spontaneous circulation: a multicentre cohort study.

Emergency medicine journal : EMJ·2026
Same author

Extensive Retrograde Dissection After Intravascular Lithotripsy Balloon Rupture: The Path of Least Resistance.

JACC. Case reports·2026
Same author

Melting temperature mapping for rapid pathogen identification in neonatal bloodstream infections: A prospective study.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

4-Galactosylkojibiose Extends the Lifespan of <i>Drosophila melanogaster</i>.

Nutrients·2026

Related Experiment Video

Updated: Jul 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Real-World Low-Density Lipoprotein Cholesterol Control After Transitioning From Evolocumab to Inclisiran.

Tatsuya Tabata1, Toshiya Chinen1, Kentaro Nakamura1

  • 1Urasoe General Hospital Okinawa Japan.

Circulation Reports
|July 10, 2026
PubMed
Summary

Inclisiran therapy effectively maintains low-density lipoprotein cholesterol (LDL-C) levels after switching from PCSK9 inhibitors. Patients with familial hypercholesterolemia may need closer monitoring for LDL-C targets.

Keywords:
Lipid managementProprotein convertase subtilisin/kexin type 9 inhibitorSecondary preventionSmall interfering RNA drug

Related Experiment Videos

Last Updated: Jul 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Genetics

Background:

  • Inclisiran is an siRNA therapy offering sustained reduction in low-density lipoprotein cholesterol (LDL-C) with biannual administration.
  • Real-world data on patients switching from PCSK9 monoclonal antibodies to inclisiran is limited.

Purpose of the Study:

  • To evaluate the effectiveness and safety of switching from evolocumab (a PCSK9 inhibitor) to inclisiran in patients with coronary artery disease.
  • To assess LDL-C level maintenance and identify patient subgroups requiring closer monitoring.

Main Methods:

  • Retrospective analysis of 32 patients with coronary artery disease who transitioned from evolocumab to inclisiran.
  • Monitoring of LDL-C levels at baseline and at 3, 6, and 9 months post-transition.

Main Results:

  • Median LDL-C levels remained stable post-switch, with values around 27-30 mg/dL throughout the 9-month follow-up.
  • 25% of patients exceeded the LDL-C target (<70 mg/dL) at least once.
  • Higher rates of exceeding LDL-C targets were observed in patients with heterozygous familial hypercholesterolemia.
  • Discontinuation rate was 12.5%.

Conclusions:

  • Switching from evolocumab to inclisiran generally maintains LDL-C control in patients with coronary artery disease.
  • Patients with familial hypercholesterolemia may necessitate more vigilant monitoring of LDL-C levels when on inclisiran therapy.